Core Viewpoint - HCW Biologics (HCWB.US) experienced a nearly 70% surge in stock price, reaching $5.81, following the announcement of a second-generation immunotherapy drug based on pembrolizumab targeting solid tumors, particularly pancreatic and ovarian cancers [1] Company Summary - The company has developed a novel proprietary TRBC product discovery and development platform technology for its new immunotherapy drug [1] - Since the introduction of immune checkpoint inhibitors (ICIs) in cancer treatment in 2011, they have been recognized as breakthrough therapies [1] - The company highlighted that preclinical and clinical studies indicate that ICIs lack co-stimulatory activity of immune cells, which diminishes their anti-tumor efficacy [1]